Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Vascular Targeting Agents

  • Michael R. Horsman
  • Dietmar W. Siemann
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6162-5



Vascular targeting agents (VTAs) are primarily cancer therapies that are specifically designed to target the vasculature of tumors and as a consequence will inhibit tumor growth and development. They may also be used to treat other pathophysiological conditions in which the tissue vasculature plays a role.



In cancer, the vascular supply to tumors is critical. For most solid tumors to grow beyond a size of a few millimeters, it is necessary for them to develop their own functional blood supply, which they do from the already established normal tissue vasculature by a process called angiogenesis. This process begins with the tumor cells secreting various angiogenic growth factors. These factors are upregulated by different environmental changes such as hypoxia, loss of tumor suppressor function, or oncogeneactivation. Of these angiogenic factors,...


Vascular Endothelial Growth Factor Ionize Radiation Therapy Vinca Alkaloid Arsenic Trioxide Corticosteroid Hormone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Clémenson C, Chargari C, Deutsch E (2013) Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol Hematol 86:143–160PubMedCrossRefGoogle Scholar
  2. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRefGoogle Scholar
  3. Folkman J (1976) The vascularisation of tumors. Sci Am 234:58–71PubMedCrossRefGoogle Scholar
  4. Horsman MR, Siemann DW (2006) Pathophysiological effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11529–11539CrossRefGoogle Scholar
  5. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727–739PubMedCrossRefGoogle Scholar
  6. Siemann DW, Horsman MR (2009) Vascular targeting therapies in oncology. Cell Tiss Res 335:241–248CrossRefGoogle Scholar

See Also

  1. (2012) Bioreductive drug. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 415. doi:10.1007/978-3-642-16483-5_645Google Scholar
  2. (2012) Tumor suppressor. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 3803. doi:10.1007/978-3-642-16483-5_6056Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Experimental Clinical OncologyAarhus University HospitalAarhusDenmark
  2. 2.Department of Radiation OncologyUniversity of FloridaGainesvilleUSA